Cargando…

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)

Detalles Bibliográficos
Autores principales:	Ghofrani, Hossein A, Hoeper, Marius M, Hoeffken, Gert, Halank, Michael, Weimann, Gerrit, Grimminger, Friedrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313404/ http://dx.doi.org/10.1186/1471-2210-9-S1-S14

Ejemplares similares

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
por: Kim, Nick H, et al.
Publicado: (2017)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
por: Marra, Alberto M., et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies
por: Stephan, Rosenkranz, et al.
Publicado: (2015)

Riociguat for pulmonary arterial hypertension associated with congenital heart disease
por: Rosenkranz, Stephan, et al.
Publicado: (2015)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Medical management of chronic thromboembolic pulmonary hypertension
por: Pepke-Zaba, Joanna, et al.
Publicado: (2017)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension
por: Wiedenroth, Christoph B., et al.
Publicado: (2018)

Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension – Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study
por: Currie, Brooke, et al.
Publicado: (2021)

The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats
por: Lang, Michaela, et al.
Publicado: (2011)

Radiological differences between chronic thromboembolic pulmonary disease (CTEPD) and chronic thromboembolic pulmonary hypertension (CTEPH)
por: Capone, Carmine, et al.
Publicado: (2021)

Depiction of mosaic perfusion in chronic thromboembolic pulmonary hypertension (CTEPH) on C-arm computed tomography compared to computed tomography pulmonary angiogram (CTPA)
por: Maschke, Sabine K., et al.
Publicado: (2021)

Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
por: Sharma, Munish, et al.
Publicado: (2021)

The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats
por: Lang, Michaela, et al.
Publicado: (2012)

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities
por: Barnikel, Michaela, et al.
Publicado: (2022)

Pharmacological therapy for patients with chronic thromboembolic pulmonary hypertension
por: Hoeper, Marius M.
Publicado: (2015)

Long-term clinical value and outcome of riociguat in chronic thromboembolic pulmonary hypertension
por: van Thor, M.C.J., et al.
Publicado: (2019)

RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
por: Hoeper, Marius M., et al.
Publicado: (2017)

Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Harzheim, Dominik, et al.
Publicado: (2013)

Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry
por: Guth, Stefan, et al.
Publicado: (2021)

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2
por: Humbert, Marc, et al.
Publicado: (2017)

Hepatorenal dysfunction in patients with chronic thromboembolic pulmonary hypertension
por: Yogeswaran, Athiththan, et al.
Publicado: (2023)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015)

Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use?
por: Le Pennec, Romain, et al.
Publicado: (2022)

Mechanisms of disease: pulmonary arterial hypertension
por: Schermuly, Ralph T., et al.
Publicado: (2011)

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
por: Cartin-Ceba, Rodrigo, et al.
Publicado: (2018)

Relationship Between Soluble ST2 Level and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) in Acute Pulmonary Embolism (PE) Patients
por: Kerkütlüoğlu, Murat, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9a3gfkltc1rdett209v93d5dmj